Under construction – not a live service
Sign in
Taking people in NetherlandsNo phase

Compares specimen PET-CT scans with surgical pathology results in cancer surgery

Checks specimen PET-CT scans against pathology findings in adults having cancer surgery.

Key facts

Who runs it
XEOS Medical
Where
Groningen, NetherlandsSee the siteAlso in 3 other countries, 4 sites
Trial code
Registry title
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
Status
Recruiting
People taking part
850 people, planned
Started
19 Nov 2025
Expected to end
15 Jan 2031
Type of study
Observational
Record updated
15 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have cancer surgery, where the removed tissue is scanned with the AURA 10 PET-CT machine.

Age
18 years or older
Sex
All sexes can join
Disease stage
People scheduled for surgery to remove a cancer (conditions listed: prostate, breast, head and neck cancer). The scan must show at least part of the main tumor.

Main reasons for not taking part

  • Under 18 years old at the time of surgery
  • Pregnant or breastfeeding women
  • Scan of the removed tissue not usable because of a technical problem or a wrongly given tracer injection
  • Not willing to give consent for use of their medical records

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • All patients that were scheduled for resective surgery and for whom successful high-resolution PET-CT imaging was performed on their resected specimens using the AURA 10 PET-CT. Successful imaging means that the image contains at least a portion of the primary tumor, the radiotracer injection was correctly executed and there were no technical issues that lead to an uninterpretable PET-CT image. Or all patients that are scheduled for resective surgery and for whom high-resolution PET-CT imaging will be performed on their resected specimens using the AURA 10 PET-CT
  • Patients willing to provide informed consent for use of their relevant medical records. For retrospectively included patients with no further Long-Term Follow-Up (LTFU) data collection, a notification will be sent

Who cannot take part

  • Under the age of 18 years at the time of resective surgery
  • Women who are pregnant or breastfeeding

Where in Netherlands

Also in 3 other countries, 4 sites

  • UMCGGroningen, NetherlandsContact: Jasper Vonk, Dr.Taking people

About the trial

What the trial wants to find out

This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings. Additionally, it assesses how these imaging insights influence clinical decision-making and long-term patient outcomes. Through this comprehensive analysis in a real-world setting, the study seeks to generate valuable insights that can enhance specimen evaluation processes and ultimately improve patient care.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Multicentric, Observational, Post-marketing, Registry Study to Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
Plain-language title
Compares specimen PET-CT scans with surgical pathology results in cancer surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 September 2026